Naoki Okuda

Naoki Okuda

Auto-generated profile, based on publicly available information

Naoki Okuda

Department of Pediatric Cardiovascular Surgery, National Cerebral and Cardiovascular Center , Osaka, Japan

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1995 in Journal Of Hypertension
Verified
Journal Article
Closed access
KYKazuo Yamada
Kazuo Yamada
AMAtsushi Moriguchi
Atsushi Moriguchi
HMHiroshi Mikami
Hiroshi Mikami
NONaoki Okuda
Naoki Okuda
JHJitsuo Higaki
Jitsuo Higaki
TOToshio Ogihara
Toshio Ogihara
Objective To investigate the effects of central amino acid neurons on the antihypertensive action of a newly developed angiotensin II type 1 receptor (AT1) antagonist, CV 11974. Materials and methods We measured the release of various amino acids in the rostral ventrolateral medulla using the brain microdialysis technique. A microdialysis probe was inserted into the exposed rostral ventrolateral medulla in male spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats anaesthetized with urethane. Mean arterial pressure and the release of amino acids (glutamate, glycine, glutamine, taurine and γ-aminobutyric acid) were monitored before and after intravenous administration of CV 11974 (5 mg/kg), nitroglycerin (5 μg/kg per min) or vehicle. Results In SHR, CV 11974 decreased mean arterial pressure (-40±6 mmHg) accompanied by significant increases in the release of inhibitory amino acids, glycine (411 ± 83%) and γ-aminobutyric acid (363 ± 71%) in the rostral ventrolateral medulla, whereas intravenous nitroglycerin produced a decrease in mean arterial pressure (-35±4 mmHg) without changes in amino acid release. In WKY rats, both intravenous CV 11974 and intravenous nitroglycerin produced smaller but significant decreases in mean arterial pressure (CV 11974, −18±5 mmHg; nitroglycerin, −20±7 mmHg) without change in the release of amino acids in the rostral ventrolateral medulla. Selective perfusion of glycine or γ-aminobutyric acid into the rostral ventrolateral medulla caused a larger mean arterial pressure reduction in SHR than in WKY rats. Furthermore, the use of a specific antagonist of glycine or of the γ-aminobutyric acid receptor in the rostral ventrolateral medulla attenuated the antihypertensive response induced by the intravenous AT1 antagonist in SHR. Conclusion The present results suggest that the release of the inhibitory amino acids glycine and γ-aminobutyric acid in the rostral ventrolateral medulla contributes to the depressor action of this AT1 receptor antagonist in the genetic hypertensive rat model.

18 February 2022 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
THTakaya Hoashi
Takaya Hoashi
KIKenta Imai
Kenta Imai
NONaoki Okuda
Naoki Okuda
MKMotoki Komori
Motoki Komori
KKKenichi Kurosaki
Kenichi Kurosaki
HIHajime Ichikawa
Hajime Ichikawa
OBJECTIVE: The aim of this study was to assess outcomes of the deferred Norwood strategy, i.e. planned Norwood following routine bilateral pulmonary artery banding and ductal stenting or continuous prostaglandin E1 administration. METHODS: Forty-five patients with hypoplastic left heart syndrome and its variants treated with the deferred Norwood strategy between 2012 and 2021 were enrolled. Mid-term outcomes were retrospectively reviewed. The median follow-up period after Norwood in hospital survivors was 4.6 years (interquartile range: 1.9, 6.8). RESULTS: Fourteen patients (31.1%) had no risk factors. The median age and weight at Norwood were 1.8 months (0.9, 3.5) and 3.1 kg (2.7, 3.6). Transplant-free survival at 6 years was 84.5%. Birth weight ≤2.5 kg and systemic atrioventricular valve (SAVV) regurgitation ≥ moderate after birth were not risk factors for mortality; body weight at Norwood ≤2.5 kg, however, was a risk factor [hazard ratio (HR), 11.3; 95% confidence interval (CI), 1.2–11; P = 0.036]. Twenty-two (48.9%) underwent Fontan with no mortalities, and 7 (15.5%) are awaiting Fontan. Freedom from SAVV surgery at 5 years was 53.1%. SAVV regurgitation ≥ moderate after birth was a risk factor for SAVV surgery (HR, 16; 95% CI, 3.6–71; P < 0.001); however, ductal stenting had a protective effect against SAVV surgery (HR, 0.09; 95% CI, 0.01–0.68; P = 0.019). Freedom from both surgical and catheter-based pulmonary artery intervention at 3 years was 27.1% CONCLUSIONS: Although deferred Norwood provided acceptable intermediate-term survival, the Fontan completion rate was unsatisfactory. SAVV surgery and pulmonary artery intervention were frequently required.

25 April 2021 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
KIKenta Imai
Kenta Imai
THTakaya Hoashi
Takaya Hoashi
NONaoki Okuda
Naoki Okuda
HOHideo Ohuchi
Hideo Ohuchi
KKKenichi Kurosaki
Kenichi Kurosaki
HIHajime Ichikawa
Hajime Ichikawa
: OBJECTIVES: The aim of this study was to identify the impact of bilateral bidirectional Glenn (BBDG) anastomosis on staged Fontan strategy and late Fontan circulation. METHODS: Of 267 patients who underwent bidirectional Glenn prior to Fontan completion between 1989 and 2013, 62 patients (23%) who underwent BBDG were enrolled in this study. Age at operation was 0.84 years (25th–75th percentile: 0.58–1.39). Thirty-three patients had heterotaxy syndrome (53%). The mean follow-up period was 12.7 ± 8.1 (max. 30.6) years. RESULTS: The overall survival rate at 15 years was 73%. Although 49 patients (79.0%) went on to Fontan completion, 12 patients (19.4%) died without achieving it. Thrombus formation and poor development in a central pulmonary artery were not observed, but obstruction of the superior vena cava (SVC) occurred in 8 patients (13%), mainly those with right atrial isomerism (P = 0.037). SVC obstruction was not, however, a risk factor for mortality (P = 0.097) or Fontan completion (P = 0.41). The shape of BBDG anastomosis, symmetricity of pulmonary blood flow, impingement of caval blood flow returning from the superior and inferior vena cavae or coexisting interrupted inferior vena cava with azygos or hemi-azygos continuation did not affect late Fontan outcomes, such as overall survival, freedom from protein-losing enteropathy or pulmonary arterio-venous malformation rates. CONCLUSIONS: SVC obstruction after BBDG frequently occurred, mainly in patients with right atrial isomerism; however, its direct impact on prognosis or achieving Fontan completion was not identified. Once Fontan circulation was established, the arrangement of the Fontan pathway did not affect late Fontan outcomes.

1 January 1995 in Japanese Heart Journal
Verified
Journal Article
Open access
KYKazuo Yamada
Kazuo Yamada
AMAtsushi Moriguchi
Atsushi Moriguchi
HMHiroshi Mikami
Hiroshi Mikami
JHJitsuo Higaki
Jitsuo Higaki
NONaoki Okuda
Naoki Okuda
TOToshio Ogihara
Toshio Ogihara